Summary of Bisphosphonate medication changes and adherence for participants that experienced side effects at Phase 2 (n = 18).

<p>Summary of Bisphosphonate medication changes and adherence for participants that experienced side effects at Phase 2 (n = 18).</p

Sample characteristics using pre-collected trial data.

<p>Sample characteristics using pre-collected trial data.</p

Additional file 1: of Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study

Figure S1. Flow chart showing recruitment of study participants. (BMP 478 kb

Summary of Patterns of Adherence.

<p>Summary of Patterns of Adherence.</p

Additional file 5: of Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study

Table S4. Adverse events leading to MTX failure for the subgroup that fulfils 2010 ACR/EULAR RA classification criteria. (DOCX 16 kb

Additional file 3: of Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study

Table S2. Adverse events leading to MTX failure. (DOCX 13 kb

Additional file 4: of Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study

Table S3. Baseline clinico-demographic variables according to reason for MTX failure (DOCX 15 kb

Additional file 2: of Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study

Table S1. Baseline and follow-up characteristics of the cohort. (DOCX 14 kb

Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial

Background- Despite effective assessment tools and medications targeting osteoporosis and related fractures, screening for fracture risk is not currently advocated in the UK. We tested whether a community based screening intervention could reduce fractures in older women. Methods- We conducted a two-arm randomised controlled trial in women aged 70 to 85 years comparing a screening programme using the FRAX risk assessment tool versus usual management. The primary outcome was the proportion of individuals experiencing one or more osteoporosis-related fractures over a five-year period. In the screening arm, treatment was recommended in women identified to be at high risk of hip fracture, according to the FRAX 10-year hip fracture probability. Findings- 12 483 eligible women, identified from primary care, participated in the trial. Of 6 233 randomised to screening, treatment was recommended in 898 (14·4%). Osteoporosis medication use was higher at the end of year one in the screening group compared to controls (15·3% vs 4·5%, respectively), with uptake particularly higher (78.3% at 6 months) in the screening high risk subgroup. Screening did not reduce the incidence of all osteoporosis-related fractures (hazard ratio: 0·94, p=0·178, 95% C.I. : 0·85 to 1·03) but there was strong evidence for a reduction in hip fractures, a pre-specified secondary outcome (hazard ratio : 0·72, p=0·002 95% C.I. : 0·59 to 0·89). There was no evidence of differences in mortality, anxiety levels or quality of life. Interpretation- A systematic, community-based screening programme of fracture risk in older women in the UK is feasible. Whilst there was no reduction in overall fracture rate the intervention was effective in reducing hip fractures by an estimated 28%. Funding- The Arthritis Research United Kingdom (ARUK), formerly the Arthritis Research Campaign (ARC), and the Medical Research Council (MRC) of the UK jointly funded this trial